Phase 3 Trial: 225-Ac-PSMA-617 + ARPI vs SOC
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxFG-3246 Advances to Phase 2 Trial in Prostate Cancer After Promising Early Results
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxMacrophage-Drug Conjugates: A New Frontier in Cancer Treatment
/0 Comments/in Delivery, Preclinical Research/by MaxAndrogen Receptor Inhibition Enhances Immune Response in Prostate Cancer
/0 Comments/in Immunotherapy, Preclinical Research/by MaxNewsletter 9/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Here we are again, spring is almost here… It has been a quiet week, without too many updates, but the ones we have are quite significant—things that can truly help us in the battle. As usual, we also have […]
Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
abiraterone acetate ADC ADT AI ai in healthcare alphafold androgen deprivation therapy antibody-drug conjugate apalutamide artificial intelligence ATM bispecific antibody bone metastasis BRCA cancer immunotherapy cancer treatment clinical trial clinical trials crispr darolutamide diet drug discovery drug repurposing drug resistance enzalutamide gut microbiome immunotherapy mcrpc metastatic cancer metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology Nectin-4 oncology oncolytic virus PARP inhibitor personalized medicine prostate cancer PSMA radioligand therapy real-world data T-cell therapy theranostics
Latest Posts
- SECuRE Trial Update: Promising Results in Metastatic Castration-Resistant Prostate Cancer March 7, 2025
- Phase 3 Trial: 225-Ac-PSMA-617 + ARPI vs SOC March 6, 2025
- FG-3246 Advances to Phase 2 Trial in Prostate Cancer After Promising Early Results March 6, 2025
- Macrophage-Drug Conjugates: A New Frontier in Cancer Treatment March 5, 2025